Selective glycoimmuno-targeting for cancer therapy

Informacje na temat projektu

SweetAim

Identyfikator umowy o grant: 716220

DOI

10.3030/716220

Projekt został zamknięty

Data podpisania przez KE 28 Listopada 2016

Data rozpoczęcia 1 Grudnia 2016

Data zakończenia 30 Listopada 2022

Finansowanie w ramach

• EXCELLENT SCIENCE - European Research Council (ERC)

Koszt całkowity

€ 1 479 995,00

Wkład UE

€ 1 479 995,00

Koordynowany przez

TEL AVIV UNIVERSITY
Israel

Periodic Reporting for period 4 - SweetAim (Selective glycoimmuno-targeting for cancer therapy)

Okres sprawozdawczy: 2021-06-01 do 2022-11-30

Podsumowanie kontekstu i ogólnych celów projektu

Cancer is a leading cause of death worldwide and new therapies are still needed. The primary objective of this proposal is to design a novel cancer therapeutic approach and to address the challenges faced by the study of carbohydrates immune recognition. It is based on findings that some tumor-associated carbohydrates can be targeted for cancer therapy. We investigated the potential of robust effective targeting of tumor-carbohydrates with antibodies both in vitro and in vivo. This research is has provided tools for designing novel therapeutics, imaging and diagnostics for cancer and for other chronic inflammation-related diseases, that are very important to reduce cancer burden for the benefit of society.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

We investigated carbohydrates as targets for antibody therapy in cancer. We explored the different factors that affect carbohydrate binding and recognition and developed several methods to improve antibody recognition and cancer killing potential both through passive therapy, as well as through active cancer vaccine design.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

We have already published fifteen papers and submitted 8 patents related to the use of antibodies for cancer diagnostics and therapy.

072120-nutri-red-meat-cancer-risk-low-resolution.jpg